Novartis pays $310 million upfront to buy IFM Tre adding portfolio of experimental antiinflammatory drugs httpswww.firstwordpharma.comnode1632487Â $NVS
Novartis pays $310 million upfront to buy IFM Tre, adding portfolio of experimental anti-inflammatory drugs https://www.firstwordpharma.com/node/1632487 $NVS
More From BioPortfolio on "Novartis pays $310 million upfront to buy IFM Tre, adding portfolio of experimental anti-inflammatory drugs https://www.firstwordpharma.com/node/1632487 $NVS"